1 / 44

Carolina Innovations Seminar February 3, 2011, 5:30-6:30pm UNC-Chapel Hill Brooks Adams, Executive Director Laura Faulc

Accelerating Commercialization in Nanobiotechnology. Carolina Innovations Seminar February 3, 2011, 5:30-6:30pm UNC-Chapel Hill Brooks Adams, Executive Director Laura Faulconer, PhD, Director Jim Roberts, Director. Topics. NC COI’s Nanobio opportunity COIN’s role Ways to participate.

naava
Download Presentation

Carolina Innovations Seminar February 3, 2011, 5:30-6:30pm UNC-Chapel Hill Brooks Adams, Executive Director Laura Faulc

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Accelerating Commercialization in Nanobiotechnology Carolina Innovations Seminar February 3, 2011, 5:30-6:30pmUNC-Chapel Hill Brooks Adams, Executive Director Laura Faulconer, PhD, Director Jim Roberts, Director

  2. Topics NC COI’s Nanobio opportunity COIN’s role Ways to participate

  3. NC Centers of Innovation / NCBC Nonprofits creating, organizing & building targeted biotech-related sectors central to economic development & job creation in NC

  4. COIs • Recognize unique strengths in NC in specific sectors that can be catalyzed by focused, collaborative efforts • Assist in tech commercialization by matching industry needs & resources with focused statewide research • Virtual centers may be regionally located serving statewide network of partners & collaborators

  5. COIs • Established by academic, industry, economic development, government consortia • Led by strong inter-university & industrial partners committed to working collaboratively • Funded COI: • Medtech / Ibiliti: www.ibiliti-nc.org • Drug Discovery: www.ddcoi.org • Nanobiotech / COIN: www.nc-coin.org • Marine Biotech

  6. Nanobio opportunity “Human health has always been determined on the nanometer scale…where the structure & properties of the machines of life work in every one of the cells in every living thing. The practical impact of nanosciences on human health will be huge.” Dr. Richard Smalley, Nobel Laureate, 1943-2005

  7. Nanobiotechnology • Application of nanotech materials, tools, & processes in the life sciences & medicine • Commercial applications: • Therapeutics & diagnostics • Medical technology & devices • Medical research • Non human health-care related COIN FOCUS Nanomedicine Cardiac progenitor cell cultures on PCL nanofibers., Duke University, Nicolas Christoforu & Kam Leong

  8. Significant federal funding

  9. The promise & challenge • Nanotech/nanobiotech is a tool box not an industry • Frequently represents platform technology • Many potential high value applications • Must play into value chain of pharma, biotech, medtech • Nanotech centers are forming globally • Industry clusters growing around them • Only a few major centers will develop “A Roadmap for Nanotechnology in NC’s 21st Century Economy,” March 2006

  10. Nanobio global market • 2009 nanomedicine market: • N America $4.75 billion • Europe $3.65 billion • Emerging nanobio companies: • US 280 • Ex-US 150 • Hubs in Boston, San Francisco, Houston, & RTP • Significant competition from Asia/China Sources: Business Insights (Jan 2010), Pew Charitable Trusts, COIN database

  11. Targeted nano-enabled delivery booming • 2010 market $6.8 billion  2015 market $21.1 billion • Drug delivery 97% of market today  90% by 2015 • Other applications: • Cosmeceuticals • Nutraceuticals • Ag & food Source: Lux Research

  12. NC recognized nanotech leader • PEN 2009 survey: • NC 8th in US • Raleigh metro 4th in US • Small Times US University Report & Rankings 2009: • Nanotech commercialization: • NCSU 3rd • UNC-CH 5th • Nanotech research: NCSU 10th

  13. NC nanobio • Gaining rapid traction • NC strong in 3 key high growth nanotech sectors: • Medicine, biotech, healthcare • Tools/instruments • Materials • Positive political-business climate supports biotech: • NC Innovation Council • Low-cost of business & high quality of life

  14. NC nanobio ecosystem • Industry • > 35 nanobio & 70 nanotech cos • > 528 bioscience cos • 400 medtech cos • Academic/nonprofit • 35 nano univ research centers • WFIRM • 2 nanotech Ph.D. programs • Among 1st with nanotech A.S. • 3 major nonprofit research institutes • Medical centers • 4 med schools • 5 teaching hospitals • Med school forming in Charlotte • Supportive infrastructure • 108 medical products CRO’s • 7 major research parks across NC • Active, engaged VCs & angels • NC Commerce • NCBC & Centers of Innovation: • NC Regional Partnerships • Entrepreneur resources • CED, BIG, BREC, other • SBTDC • Southeast TechInventures (STI) • First Flight & univ-based incubators

  15. NC nanobio companies Drug Discovery and Delivery Asklepios Biopharma Chapel Hill BioDelivery Sciences Raleigh Branthan Laboratories Greensboro Cromoz Research Triangle Park Helia Medical Raleigh Liquidia Durham Micell Technologies Raleigh NanIO Biosciences Research Triangle Park NanoCor Therapeutics Chapel Hill NanoMed Corp Greensboro NanoVector Raleigh Peptagen Raleigh PharmAgra Laboratories Brevard Qualiber Chapel Hill Salzburg Therapeutics Winston Salem Thermiacure Greensboro Advanced Medical Technology Advanced Liquid Logic Morrisville Biomedomics Durham Centice Morrisville Dental Safe Greensboro Expression Analysis Durham Filtara Cary Inanovate Research Triangle Park Laam Science Morrisville NanoArt Durham Novan Research Triangle Park Nanomics Biosciences Cary Pioneer Surgical Orthobio/Greenville  Optotrack Cary QuarTek International Greensboro XinRay Systems Research Triangle Park Other Blue Nano Cornelius NanoTech Labs Yadkinville Specialty Scientific High Point Xanofi Raleigh

  16. Liquidia Technologies • Developing highly precise particle-based vaccines & therapeutics for prevention & treatment of human disease • Combining deep understanding of particle-based drug development with breakthrough small molecule & biological therapeutics to engineer vaccines & therapies with potential to dramatically improve quality of human life • Based on PRINT® technology developed in UNC Prof Joe DeSimone’s lab Neal Fowler, CEO Founded 2004 Located in Durham www.liquidia.com

  17. XinRay • Developing & manufacturing distributed x-ray sources for a broad range of applications including: Diagnostic medical, imaging, homeland security, industrial inspection • Carbon nanotube technology derives from core technologies licensed from UNC-CH & Duke Moritz Beckmann, CEO Founded 2007 Located in RTP www.xinraysystems.com

  18. Qualiber • Developing NanoGTP (gemcitabine triphosphate), a novel nanoparticle-based treatment for lung, pancreatic, and other cancers • Utilize enabling Lipid-Calcium-Phosphate Nanoparticle drug delivery platform developed in UNC Prof Leaf Huang’s lab Anil Goyal, CEO Founded in 2010 Virtual Company www.qualiberinc.com

  19. NC univ leaders in nano-enabled drug delivery • University Texas • Harvard University • MIT • University of Michigan • Johns Hopkins University • University of Illinois • Northwestern University • University of Washington • Purdue University • University of Utah • GA Institute of Technology • Washington University • University of Florida • University Pennsylvania • Cornell University • Univ of CA at Berkeley • University of Massachusetts • Univ of CA at San Francisco • University of Minnesota • NCI • Rice University • Ohio State University • Univ of CA at Los Angeles • Univ of CA at Santa Barbara • University Nebraska • UNC • University of Wisconsin • Penn State University • Massachusetts General Hospital • University of Kentucky • Stanford University • University of Maryland • University of Southern California • University of Pittsburgh • University of California at Davis • Emory University • SUNY Buffalo • University of California at San Diego • Northeastern University • Carnegie Mellon University • NC State University • Vanderbilt University • Case Western Reserve University • Duke University • Brown University • CALTECH • Arizona State University • Columbia University • Rutgers State University • University of Delaware Source: COIN study 2009; Based on peer-reviewed articles in Web of Science®

  20. Thought leaders in nano drug delivery UNC-CH • Leaf Huang • Joe DeSimone • Rudolph Juliano • Wenbin Lin • Russ Mumper Duke • Ashutosh Chilkoti • Kam Leong • NCSU • Nancy Monteiro-Riviere • Roger Narayan Source: COIN study 2009; Based on peer-reviewed articles in Web of Science®

  21. COIN’s role Address unmet needs of nanobio community: Business intelligence Networking & high value connections Tech scouting & industry partnering Early-stage funding Preclinical testing & regulatory guidance

  22. COIN key facts • Nonprofit 501c3 launched June 2009 • $2.6 million funds committed • COIN: Economic/business development catalyst advancing nanobiotech/nanomedicine commercialization • Key asset: Knowledge & network in nanomedicine • Customers: Researchers, entrepreneurs, product developers, business managers, & investors in nanobiotech • Scope: NC & US • Sustainability: Event sponsors/registrations & member clients

  23. COIN programs • Premier conference/networking events & workshops • Build, connect, & inform the community… • Nanobiotech Executive Roundtables • Annual NC Nanotech Commercialization conference • nanobio/nanomedicine content • NanoBioConnect: • Knowledge-rich web portal providing open access… • Trusted business intelligence • Directory/compendium of resources • Innovation services: • Address specific obstacles to commercialization… • Grant writing • Incubation partners • Connections for pre-clinical testing

  24. Desired end-game commercial outcomes • Licenses • Product concepts move into clinic • Product launches • Funding events • New co formations/growth & co expansions • Job growth • Wealth creation • Tool & service providers achieve financial goals

  25. Accomplishments: Building the organization • First COI funded & launched • 4 full-time hires: • Brooks Adams  Strategy & program management • Laura Faulconer  Content • Jim Roberts  Connections • Clare Valcore  Logistics • Others professional resources: • 21 university interns to date  Analytics • Outsource finance, marketing, & IT • BOD: 7 outside directors, cross section of nanobio ecosystem • SAB: 7 key thought leaders from academia & industry • New 2400 sq ft HQ, Downtown Durham: • Dedicated collaboration meeting space • Kymanox bullpen for interns & visitors

  26. Some great partners!

  27. Ways to participate: Events March – NC Nano Commercialization (Charlotte) May – NanoBio Executive Roundtable (Triangle) August – MANCEF COMS (Greensboro)

  28. Accomplishments: Events • NCNCC 2010:Nanomed track – 5 speakers/50 attendees • NCNCC 2011: • Workshop, Nanobio Track, Funding Pitch Room, & Exhibit • 21 speakers confirmed (more coming) • 2 of 5 pitch room participants signed on • Roundtables: 3 events, 20 talks, 215 attendees from 8 states • COIN showcasing exhibit: 3 events • NCNCC (Greensboro) • Medtech (Triangle) • NNI Summit (D.C.) • Talks by COIN staff: Brooks 8, Laura 3, Jim 1 • COMS: Recruited with $53K funding commitment secured COIN / Slide 7

  29. When can you get involved? • NC Nanotechnology Commercialization Conference • March 29-30, 2011 • Charlotte, NC • COIN nanomedicine workshop morning of March 29 • COIN nanobio track in afternoon March 29 • Conference keynote speakers include • Travis Earles, White House Office of Science & Technology Policy • Doug Jamison, CEO, Harris & Harris

  30. How and when can you get involved? • MANCEF COMS, based in New Mexico • August 28th, 2011 • 500-700 people • 45% international participation • NCBC, RTI, NC Commerce, Joint School of Nano • Lockheed Martin (energy) • Most federal granting organizations • Norway 2012

  31. Ways to participate: Media & NanoBioConnect

  32. Raising the profile together • Raise profile of our community & our accomplishments: • Routine press releases  8 to date, more in pipeline • Strong media partnerships  LTW, TJS, MedCity News, Nanomedicine Journal • Routine coverage  LocalTechWire, TechJournal South, Triad Business Journal, Business NC, NanotechNow, AZO Nano, Nanowerk, NC Commerce Newsletter • Thought leadership  White papers & articles for technical & scientific journals • Joint press releases with community

  33. NanoBioConnect • Web-based portal for business intelligence & open innovation in nanomedicine • Profiles of companies, university centers, research institutes • Profiles of service providers with nano expertise • Interview with key thought leaders • White papers and reports • Candidate portal • Launched January 2011 with NC-coverage, rapidly growing to US coverage

  34. Accomplishments: Web/social media • NanoBioConnect: • Since soft launch November: • 1,866 visitors , 1,047 unique visitors • 8,630 page views, 4.62 pages/visit • 5:24 min average • 52.09% new visitors • At least a hit from every continent; Most from US, Canada, India, UK • Most popular: homepage, NanoBioConnect, about us, community • January full launch with press release: • Profiles: • 29 coos (Plus 8 in QC, 85 in preparation draft) • 5 people • 1 research institute • 19 service providers • White papers & reports: 4 • Newsletters: 1 • Social media/web: • 5 venues  companies, LinkedIn, Twitter (300 followers!), YouTube, Wikipedia

  35. NanoBioConnect next goal • Develop a robust listing of preclinical testing and contract R&D resources with expertise in nano with national coverage

  36. NC resources for pre-clinical testing

  37. UNC Translational Oncology & Nanoparticle Drug Development Initiative Lab & GLP Bioanalytical Facility • Part of UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, & Carolina Center of Cancer Nanotechnology Excellence: • An analytical chemistry & pharmacology lab focusing on pharmacologic characterization & translational development of small molecule & nanoparticle anticancer agents • Has unique methods & technologies fundamental to development of nanoparticle agents • Performs formulation, stability, efficacy, toxicity, phenotypic probe, pharmacokinetic & pharmacodynamic studies of nanoparticle agents Bill Zamboni, Director Founded 2009 Located in Chapel Hill http://www.unclineberger.org/research/cores/facility.asp?facilityID=3

  38. Ways to participate: Grant writing services

  39. Grants to accelerate translation • COIN offers grant-writing & other services to accelerate technology translation and development • Contract grant-writing  Nominal hourly rate with significant savings over traditional agency • Partnership to submit grants • Assistance identifying grant opportunities • Assistance identifying collaborators • Support of grants  Letters of support, commitment • Southeast TechInventures partnership

  40. Summary

  41. COIN offers • Innovators & entrepreneurs: Resources to build relationships crucial for technology translation & business development • Industry partners: Single point of entry to nanobiotech sectors in NC and access to innovators & entrepreneurs • Service providers: Resources to develop nanobiotech project pipeline

  42. Summary • Market opportunity is apparent but not without challenges • NC has the assets to continue to be a major player in nanobio • COIN can and will play on the state & national stages • COIN is coalescing the nanobio community focusing on key issues • Together we can accelerate commercialization in nanobiotechnology

  43. The Venable Center 303 S Roxboro St., Ste 30, Durham, NC 27701 Office: (919) 680-2070 Fax: (919) 680-2906 www.nc-coin.org www.linkedin.com/companies/ coin-center-of-innovation-for-nanobiotechnology @NCNanoBioTech

More Related